AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
London close: Stocks mixed on corporate updates, trade developments
29 July 2025 16:28
(Sharecast News) - London stocks ended Tuesday on a mixed note as a wave of corporate results kept investors busy and market participants continued to assess the implications of the recent US-EU trade deal.
-
Astrazeneca H1 gross profits up 10pc as 'strong growth momentum' continues
29 July 2025 07:09
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline delivery" in the year-to-date.
-
London close: Stocks reverse gains to finish lower
28 July 2025 17:16
(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union.
-
AstraZeneca reports positive results from autoimmune treatment trial
24 July 2025 08:27
(Sharecast News) - AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for...
-
AstraZeneca to invest $50bn in US manufacturing and R&D
22 July 2025 07:06
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it plans to invest $50.0bn in the US for medicines manufacturing and R&D by 2030.
-
London close: Stocks fall after rise in UK consumer inflation
16 July 2025 17:49
(Sharecast News) - London equities slipped on Wednesday as stronger-than-expected UK inflation data offset a decline in US producer inflation, prompting investor caution over the interest rate outlook.
-
AstraZeneca drug fails to meet main goal in late-stage amyloidosis trial
16 July 2025 07:31
(Sharecast News) - An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.
-
London close: Stocks rise despite renewed trade tensions
14 July 2025 17:45
(Sharecast News) - London stocks closed higher on Monday, buoyed by geopolitical trade developments after US president Donald Trump announced plans to impose 30% tariffs on imports from the European Union...
-
Berenberg raises target price on AstraZeneca
9 July 2025 09:01
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker AstraZeneca from £140 to £142 per share on Wednesday, citing "strong pipeline readouts" which were yet to be...
-
Sunday newspaper round-up: Trade, AstraZeneca, Tax hikes
6 July 2025 12:41
(Sharecast News) - Brussels is heading into a critical week, with just two to go to clinch a trade agreement with the US or face a 50% levy on its exports. At stake are €1.6trn in transatlantic trade....
-
London close: FTSE finishes flat ahead of Trump tariff deadline
4 July 2025 17:48
(Sharecast News) - London stocks ended Thursday little changed at the top tier but weaker further down the board, as investors weighed fresh economic data and cautious sentiment ahead of Donald Trump's...
-
AstraZeneca's Imfinzi gets EU green light
4 July 2025 07:10
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.
Company announcements Announcements
-
H1 and Q2 2025 results
29 July 2025 07:00
AstraZeneca
-
Gefurulimab nanobody met Phase III endpoints
24 July 2025 07:00
AstraZeneca
-
AstraZeneca plans to invest $50bn in the US
22 July 2025 07:00
AstraZeneca
-
Update on anselamimab in AL amyloidosis
16 July 2025 07:00
AstraZeneca
-
Baxdrostat met primary endpt in BaxHTN PhIII trial
14 July 2025 07:00
AstraZeneca
-
Imfinzi approved in the EU for bladder cancer
4 July 2025 07:00
AstraZeneca
-
Total Voting Rights
1 July 2025 15:00
AstraZeneca
-
Datroway approved in US for EGFRm lung cancer
24 June 2025 07:00
AstraZeneca
-
Holding(s) in Company
17 June 2025 11:45
AstraZeneca
-
AstraZeneca enters into collaboration with CSPC
13 June 2025 09:30
AstraZeneca
-
Director/PDMR Shareholding
12 June 2025 15:00
AstraZeneca
-
Fixed-duration Calquence approved in EU for 1L CLL
6 June 2025 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.